CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 238 enrolled
Drug / intervention
CHS-1420 +1 morebiological
Likely dose
CHS-1420 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07147257
NCT07147257Phase 1Completed
CompareCT.gov

A Single-Center, Randomized, Single-Blind, Single-Dose, Parallel-Group Trial to Assess the Pharmacokinetic Similarity Between CHS-1420 40 mg/0.4 mL and HUMIRA® (Adalimumab) 40 mg/0.4 mL in Healthy Chinese Adult Participants Under Fasting Conditions

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.·interventional·Posted Aug 29, 2025·Updated Jan 28, 2026

In Brief

A Phase 1 clinical trial evaluating CHS-1420 and HUMIRA® for Healthy Participants. Completed, enrolled 238 participants across 1 site.

Detailed Summary

A Single-Center, Randomized, Single-Blind, Single-Dose, Parallel-Group Trial to Assess the Pharmacokinetic Similarity Between CHS-1420 40 mg/0.4 mL and HUMIRA® (Adalimumab) 40 mg/0.4 mL in Healthy Chinese Adult Participants under Fasting Conditions

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Participants
CountriesChina
Collaborators--

Timeline

Phase 1CompletedFinished
20252026
First PostedAug 29, 2025
Enrollment StartFeb 12, 2025
Primary CompletionMay 6, 2025
Study CompletionMay 29, 2025
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 10 months ago

Interventions

CHS-1420biological

Dose of 40 mg will be subcutaneously administered to participants in

HUMIRA®biological

Dose of 40 mg will be subcutaneously administered to participants in